Skip to main content
  • Main menu
  • User menu
  • Search
  • English ▼
    • English
    • Afrikaans
    • Albanian
    • Amharic
    • Arabic
    • Armenian
    • Azerbaijani
    • Basque
    • Belarusian
    • Bengali
    • Bosnian
    • Bulgarian
    • Catalan
    • Cebuano
    • Chichewa
    • Chinese (Simplified)
    • Chinese (Traditional)
    • Corsican
    • Croatian
    • Czech
    • Danish
    • Dutch
    • Esperanto
    • Estonian
    • Filipino
    • Finnish
    • French
    • Frisian
    • Galician
    • Georgian
    • German
    • Greek
    • Gujarati
    • Haitian Creole
    • Hausa
    • Hawaiian
    • Hebrew
    • Hindi
    • Hmong
    • Hungarian
    • Icelandic
    • Igbo
    • Indonesian
    • Irish
    • Italian
    • Japanese
    • Javanese
    • Kannada
    • Kazakh
    • Khmer
    • Korean
    • Kurdish (Kurmanji)
    • Kyrgyz
    • Lao
    • Latin
    • Latvian
    • Lithuanian
    • Luxembourgish
    • Macedonian
    • Malagasy
    • Malay
    • Malayalam
    • Maltese
    • Maori
    • Marathi
    • Mongolian
    • Myanmar (Burmese)
    • Nepali
    • Norwegian
    • Pashto
    • Persian
    • Polish
    • Portuguese
    • Punjabi
    • Romanian
    • Russian
    • Samoan
    • Scottish Gaelic
    • Serbian
    • Sesotho
    • Shona
    • Sindhi
    • Sinhala
    • Slovak
    • Slovenian
    • Somali
    • Spanish
    • Sudanese
    • Swahili
    • Swedish
    • Tajik
    • Tamil
    • Telugu
    • Thai
    • Turkish
    • Ukrainian
    • Urdu
    • Uzbek
    • Vietnamese
    • Welsh
    • Xhosa
    • Yiddish
    • Yoruba
    • Zulu

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

English ▼
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scottish Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sudanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticleRadiopharmacy & Adjunctive Medications

Validation of an Ergonomic Method of Withdrawing 99mTc-Radiopharmaceuticals

Sandy Blondeel-Gomes, Solène Marie, Sabrina Loyeau, Julien Fouque, François Lokiec and Olivier Madar
Journal of Nuclear Medicine Technology March 2018, 46 (1) 49-52; DOI: https://doi.org/10.2967/jnmt.117.199133
Sandy Blondeel-Gomes
1Department of Radio-Pharmacology, Institut Curie Hospital, Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solène Marie
1Department of Radio-Pharmacology, Institut Curie Hospital, Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabrina Loyeau
2Operational Hygiene Team, Institut Curie Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julien Fouque
1Department of Radio-Pharmacology, Institut Curie Hospital, Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Lokiec
1Department of Radio-Pharmacology, Institut Curie Hospital, Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Madar
1Department of Radio-Pharmacology, Institut Curie Hospital, Paris, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The main objective of the present work was to ensure the quality of radiopharmaceutical syringes withdrawn with a system consisting of a spinal needle and an obturator IN-Stopper. Methods: Visual examinations and physicochemical tests were performed at baseline and 4 h for 99mTc-albumin nanocolloid and at baseline and 7 h for 99mTc-eluate, 99mTc-hydroxymethylene diphosphonate, and 99mTc-human serum albumin. Microbiologic validation was performed according to the European pharmacopoeia. Fingertip radiation exposure was evaluated to confirm the safety of the system. Results: The results showed stable visual and physicochemical properties. The integrity of the connector was not affected after 30 punctures (no cores). No microbiologic contamination was found on tested syringes. Concerning radiation safety, no overexposure was reported with the system. Conclusion: The system could be used 30 times. The stability of syringes withdrawing radiopharmaceuticals with this method is guaranteed up to 4 h for 99mTc-albumin nanocolloid and 7 h for 99mTc-eluate, 99mTc-hydroxymethylene diphosphonate, and 99mTc-human serum albumin.

  • quality assurance
  • 99mTc
  • radiopharmaceuticals
  • radiopharmacy

To reduce personal exposure to γ-radiation, 99mTc-radiopharmaceutical vials are placed in tungsten shields with lead glass. Doses are usually prepared by reversal of the vial in order to withdraw the prescribed dose in a syringe. Shielded vials weigh between 900 g and 2 kg. Syringes are also manipulated with a shield device whose weight is almost 200 g. Because of the heaviness of the material, repetition of these actions induces serious physical demands on the staff.

In our department, a method avoiding reversal has been validated for 18F-radiopharmaceutical dispensing. It consists of introducing a spinal needle connected to a membrane obturator IN-Stopper (B. Braun) (1) into the vial. The length of the needle allows for withdrawal of the totality of the liquid contained in the vial without reversal. The doses are dispensed by inserting the assembled needle and syringe into the obturator.

The use of the spinal needle and IN-Stopper would improve ergonomics, but a validation must be performed to guarantee the quality of the syringes drawn. Several interactions between medical device and radiopharmaceutical have been amply described (2), and process validation is necessary (3).

According to the manufacturer’s recommendations, the obturator in the stopper can be punctured only 10 times by a 0.6-mm-diameter needle, which corresponds to our practice for 18F-radiopharmaceuticals. 99mTc-radiopharmaceutical preparations are multidose vials, and in our department, 10 doses could be filled from one vial. The recommended number of uses of the connector would be exceeded because of readjustment of the dose needed to obtain the prescribed dose. Thus, the obturator integrity is not guaranteed, and a microbiologic risk exists. To ensure radiation safety, an evaluation is also necessary before routine use by staff.

The use of this method to withdraw 99mTc-radiopharmaceutical preparations (up to now used for 18F-radiopharmaceuticals) requires a visual examination, a physicochemical and microbiologic validation, and a radiation safety evaluation.

MATERIALS AND METHODS

Tests were performed in a class A shielded hood (Tema Sinergie).

To limit the risk that rubber cores would form, a Quincke needle (Vygon), 18-gauge and 90 mm in length, was put into the vial’s cap using the stylet. The stylet was removed and an obturator top, IN-Stopper, was connected to the spinal needle. The system is represented in Figure 1. The dose was withdrawn into a syringe (Plastipak; BD Medical) connected to a needle, Microlance 3 (Becton Dickinson), 25 mm in length and 23-gauge, by piercing the rubber part of the connector. Shielded vials (Medisystem) weigh 915 g and shielded syringes (Medisystem) 172 g.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Photo of withdrawal system: spinal needle assembled to membrane obturator IN-Stopper.

Visual Examination and Physicochemical Controls

The system was tested with the following solutions: 99mTc-pertechnetate eluate, 99mTc-hydroxymethylene diphosphonate (99mTc-HMDP) (Osteocis; IBA Molecular), 99mTc-albumin nanocolloid (Nanocoll; GE Healthcare), and 99mTc-human serum albumin (99mTc-HSA) (Vasculocis; IBA Molecular).

99mTc-sodium pertechnetate was eluted from a Drytec 99Mo/99mTc generator (GE Healthcare). The 99mTc-radiopharmaceuticals were prepared following the manufacturer’s instructions. The studied system was introduced into vials before the content for first quality control test was withdrawn (baseline). The stability study was performed for 7 h for 99mTc-eluate (n = 5), 99mTc-HMDP (n = 5), and 99mTc-HSA (n = 5) and for 4 h for 99mTc-albumin nanocolloid (n = 5). Luer slip connector syringes with a capacity of 1 mL (Plastipak) were used for sampling. Vials were stored at room temperature throughout the study. Organoleptic specifications detailed in the product-characteristic summary were checked by a visual examination. pH was determined by pH indicator strips (MColorpHast; Merck Millipore).

Radiochemical purity was tested by instant thin-layer chromatography. For 99mTc-pertechnetate eluate, 99mTc-HSA (4), and 99mTc-albumin nanocolloid (5), the method required Whatman 31ET strips (Clerad; Biodex) and acetone as solvent (GPR Rectapur; VWR). Concerning 99mTc-HMDP, the radiochemical purity was determined by a 2-strip procedure (5): instant thin-layer chromatography–silica gel strips and distilled water as solvent were used to determine the percentage of reduced or hydrolyzed 99mTc, and Whatman 31ET strip and acetone as solvent were used to evaluate the percentage of free pertechnetate.

After migration of the solvent, paper strips were scanned with a sodium iodine crystal detector on a MiniGITA Star (Elysia Raytest). Chromatograms were recorded and analyzed with GINA-Star thin-layer chromatography (version 5.8).

Visual Examination of IN-Stopper Connector

The IN-Stopper membrane was examined for integrity and for the absence of small cores or plugs.

Sterility Test

The sterility tests were performed on 3 different days by 3 different operators. The rubber cap of the growth medium vial was cleansed with a chlorhexidine-sterilized pad before being punctured by the system. Each day, 10 syringes per operator (total, 30) were prepared with the spinal needle and IN-Stopper up to 7 h after the introduction of the system into the growth medium vial. Syringes were withdrawn at regular time intervals. Each 2.5-mL Luer slip connector syringe was prepared following the same protocol to simulate volume readjustment: IN-Stopper connector cleaned with chlorhexidine-sterilized pad; 1.5 mL of broth withdrawn into syringe; needle removed and then inserted; 1 mL withdrawn into growth medium vial; needle removed and then inserted; 0.5 mL of broth withdrawn into syringe (final volume, 1 mL); needle disassembled and then assembled with 0.22-nm Perifix filter (B. Braun); hood air withdrawn; and filter disassembled and then assembling with a cap (Vygon).

The growth medium vials were stored at room temperature during the study.

Experimental conditions were validated by a positive control and a negative control. The positive control syringes were inoculated with Staphylococcus aureus and Aspergillus brasiliensis growth. Sterile water was used for the negative control. A positive transport sample and a negative transport sample were also prepared in syringes to validate transport conditions.

Each day, syringes were collected by Bioclin Laboratory. Microbiologic cultures were performed by Bioclin Laboratory according to the European Pharmacopoeia, 8th edition (6). Samples (spinal needle and IN-Stopper tests, positive control, negative control, positive transport sample, negative transport sample) were divided into 2 equal parts and directly inoculated onto 2 different media. Fluid thioglycolate medium and soybean casein digest broth were incubated at 30°C–35°C and at 20°C–25°C, respectively, for 14 d, with the exception of the positive control, which was incubated for 5 d.

Fingertip Radiation Exposure and Contamination

A fingertip radiation dosimeter, Nuclear Educational Dosimeter (Unfors Instruments), was attached to the distal medial aspect of the index finger and covered with a pair of latex examination gloves. Tests were performed on the right index finger and then on the left index finger of each operator.

Dosimetry was measured and compared for 3 operators for both procedures: a routine process involving disinfection of the vial cap followed by reversal withdrawal of one syringe, and a spinal needle/obturator process consisting of insertion of the system into the vial followed by disinfection of the obturator and withdrawal of one syringe. The vials used for the tests were filled with 99mTc-pertechnetate eluate. Vials were measured using a dose calibrator, CRC 25R (Capintec), to calculate the received dose per megabecquerel for each hand.

Spillage and radioactive contamination were also studied. A contamination detector, LB 124 (Berthold), was used to measure radioactivity on shielded hood, gloves, vials, and syringe shields. Areas that registered more than twice the previously determined background level were considered contaminated.

RESULTS

Characteristics of Tested Preparation

The recommendations of the product-characteristic summary were followed for all preparations. Table 1 summarizes all preparation characteristics (activity and volume).

View this table:
  • View inline
  • View popup
TABLE 1

Activity and Volumes of Preparations

Visual Examination and Physicochemical Controls

The eluates and the preparation remained limpid and free from rubber coring. The physicochemical results are specified in Table 2. The results met the specifications of the product-characteristic summary and showed 7-h stability for 99mTc-eluate, 99mTc-HMDP, and 99mTc-HSA and 4-h stability for 99mTc-albumin nanocolloid according to those parameters.

View this table:
  • View inline
  • View popup
TABLE 2

Physicochemical Results for Controls

Visual Examination of IN-Stopper Connector

No cores or plugs were observed on the vial caps, and the integrity of the obturator had not been affected after 30 punctures.

Sterility Test

The positive control and the positive transport sample showed microbiologic contamination in both media for all samples. For syringes withdrawn with the spinal needle and IN-Stopper, the negative control and the negative transport sample remained free of microbiologic contamination in both media. These results prove that syringes drawn with the spinal needle and IN-Stopper are microbiologically stable for up to 7 h.

Fingertip Radiation Exposure and Contamination

The results showed an important reduction in the cumulative fingertip radiation dose for the dominant hand when the spinal needle and IN-Stopper was used, compared with the reversal method. Only the dominant hand received a dose during introduction of the system into the rubber cap. This dose remained low, compared with that received during the reversal procedure. There was no spillage of the radioactive solution during the tests, and no contamination was found. The results are summarized in Table 3.

View this table:
  • View inline
  • View popup
TABLE 3

Activity of 99mTc-Pertechnetate Eluate Vials and Dosimetry of Dominant and Nondominant Hands

DISCUSSION

99mTc-radiopharmaceuticals are usually withdrawn by vial reversal. To avoid these reversal movements, long needles are ideal and allow for withdrawal of virtually all the preparation. We previously used Sterican needles (60-mm, 23-gauge; B. Braun). Withdrawal was done by puncturing the vial cap several times to adjust the dose in order to obtain the prescribed activity. However, the needles were flexible and oscillated during removal of the vial’s cap, creating radioactive microdroplets and exposure of the extremities of staff to radiation.

As a result, we finally chose a spinal needle to put into the vial’s cap. To prevent air contamination of the preparation, other teams tried to connect a bidirectional valve to the spinal needle, but this presents drawbacks such as the impossibility of use with a Luer slip syringe, an increase in exposure to radiation (7), and a risk that the work environment will be contaminated with radioactivity (8). IN-Stopper connectors were chosen because they allow use of both Luer slip and Luer-Lok slip syringes. Luer slip syringes are preferred by technologists for peripheral injections, but Luer-Lok slip syringes are preferred for securing central injections. The 23-gauge needle diameter allows for easy withdrawal and reduces the risk that rubber cores will form (9,10). In our study, we proved that although the manufacturer recommended only 10 uses, the IN-Stopper connector could safely be used 30 times.

The conditions of the study followed routine practice. The 99mTc-radiopharmaceuticals tested were those most often prepared in the department. In fact, we dispense syringes for up to 7 h for 99mTc-HMDP, 99mTc-HAS, and 99mTc-eluate and for up to 4 h for 99mTc-albumin nanocolloid. A maximum of 10 syringes could be withdrawn from one multidose preparation. Eluate withdrawal is necessary for 99mTc-radiopharmaceutical preparation. Thus, we also performed tests on the eluate. Levigoureux et al. had already proved the nonmicrobiologic contamination of multidose radiopharmaceuticals when the rules of hygiene are applied (11). Furthermore, the radioactive nature of radiopharmaceuticals cannot guarantee sterility (12). The study was performed under worst-case conditions: vials stored at room temperature and disinfection of the obturator cap only once for a syringe preparation. The cap obturator was not disinfected before dose adjustment and a new puncture.

Syringes were filled with air to allow aerobic microbial growth. Air was filtered to avoid external microbial contamination during the tests. Assessments on vials would have been easier, but to ensure the quality of the radiopharmaceuticals injected into the patient, microbiologic tests on syringes were preferred.

Concerning radiation safety, the system does not increase the fingertip dose even if there is an additional step: insertion of the spinal needle in the rubber cap before the first drawing. Furthermore, the nondominant hand does not touch the vial containing the radioactive solution.

The cost of the system (IN-Stopper obturator and spinal needle) is calculated at €0.815 ($0.97), excluding taxes. This cost corresponds to an annual cost of less than €1,300 ($1,542.97) for 1,500 preparations.

Staff immediately accepted this new withdrawal method that improves ergonomics. Despite all these benefits, 2 risks remain: needle stick injury and internal radioactive contamination. These risks can be reduced by use of a needle recapper (13).

This study showed that eluate and preparation characteristics (visual and physicochemical) are not influenced by the system. Furthermore, we proved that administered syringes remained sterile and free from rubber coring.

CONCLUSION

When withdrawn with the spinal needle and IN-Stopper, 99mTc-eluate, 99mTc-HMDP, and 99mTc-HSA syringes are guaranteed to be stable for up to 7 h, and 99mTc-albumin nanocolloid is guaranteed for up to 4 h. This method strikes a good balance among radiation safety, hygiene, and ergonomics. This method must be validated for other radiopharmaceuticals before widespread use.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Nov. 10, 2017.

REFERENCES

  1. 1.↵
    IN-stopper. Europharmat website. http://base.euro-pharmat.com/pub_dm/fiche-dispositif-medical.aspx?id=14283. Updated August 27, 2012. Accessed December 21, 2017.
    Google Scholar
  2. 2.↵
    1. Hung JC,
    2. Ponto JA,
    3. Hammes RJ
    . Radiopharmaceutical-related pitfalls and artifacts. Semin Nucl Med. 1996;26:208–255.
    OpenUrlCrossRefPubMedGoogle Scholar
  3. 3.↵
    1. Del Carmen Plancha-Mansanet M,
    2. Caballero-Calabuig E,
    3. Félix-Fontestad J,
    4. et al
    . Stability of stabilized 99mTc-d,l-HMPAO stored in vials and syringes. J Nucl Med Technol. 2008;36:213–216.
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  4. 4.↵
    1. Zimmer AM,
    2. Pavel DG
    . Rapid miniaturized chromatographic quality-control procedures for Tc-99m radiopharmaceuticals. J Nucl Med. 1977;18:1230–1233.
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  5. 5.↵
    1. Robbins PJ
    . Chromatography of Technetium-99m Radiopharmaceuticals: A Practical Guide. Reston, VA: Society of Nuclear Medicine and Molecular Imaging;1984.
    Google Scholar
  6. 6.↵
    General methods. 2.6 biological methods. 2.6.1 sterility 07/2010:20601. In: European Pharmacopoeia. 8th ed. Strasbourg, France: Council of Europe; 2014.
    Google Scholar
  7. 7.↵
    1. Galvez D,
    2. Cormier N,
    3. Blandin M,
    4. Renard PY,
    5. Froger S
    . Sécurisation de la préparation et de l’administration de médicaments radiopharmaceutiques (MRP): comparaison dosimétrique de valves bidirectionnelles. Europharmat congress website. http://www.euro-pharmat.com/communications-2016/download/938/1892/170. Presented 2016. Accessed December 21, 2017.
    Google Scholar
  8. 8.↵
    1. Le Garlantezec P,
    2. Rizzo-Padoin N,
    3. Aupee O,
    4. et al
    . Evaluation of the performance of transfer devices in a closed system using a radioactive solution of [99mTc] [in French]. Ann Pharm Fr. 2011;69:182–191.
    OpenUrlPubMedGoogle Scholar
  9. 9.↵
    1. Campagna R,
    2. Pessis E,
    3. Guerini H,
    4. et al
    . Occurrence of coring after needle insertion through a rubber stopper: study with prednisolone acetate. Eur Radiol. 2013;23:424–427.
    OpenUrlGoogle Scholar
  10. 10.↵
    1. Ponto JA
    . Self-sealing capacity of vial stoppers after multiple needle punctures. J Am Pharm Assoc (2003). 2013;53:58–60.
    OpenUrlGoogle Scholar
  11. 11.↵
    1. Levigoureux E,
    2. Hoffman A,
    3. Brun J,
    4. et al
    . Handling of radiopharmaceuticals drugs in hot cell: Implementation and validation of new hygiene procedures [in French]. Pharm Hosp Clin. 2012;47:106–115.
    OpenUrlGoogle Scholar
  12. 12.↵
    1. Jörg G,
    2. Fosselmann M,
    3. Leis W,
    4. et al
    . Inhibition of viability of microorganisms in [18F]-labeled radiopharmaceuticals. Nucl Med Biol. 2017;44:105–113.
    OpenUrlGoogle Scholar
  13. 13.↵
    Guidance on the recapping of needles in radiopharmacy and nuclear medicine. U.K. Radiopharmacy Group website. https://www.bnms.org.uk/images/Recapping_needles_UKRG_guidance_v5_UKRG_format.pdf. Published 2013. Accessed December 21 2017.
    Google Scholar
  • Received for publication July 11, 2017.
  • Accepted for publication October 5, 2017.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 46 (1)
Journal of Nuclear Medicine Technology
Vol. 46, Issue 1
March 1, 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Share
Validation of an Ergonomic Method of Withdrawing 99mTc-Radiopharmaceuticals
Sandy Blondeel-Gomes, Solène Marie, Sabrina Loyeau, Julien Fouque, François Lokiec, Olivier Madar
Journal of Nuclear Medicine Technology Mar 2018, 46 (1) 49-52; DOI: 10.2967/jnmt.117.199133
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Assessment of Residual [99mTc]Tc-Tetrofosmin Activity in Routine Nuclear Medicine Practice at Hospital Kuala Lumpur
  • Investigation of the Importance of Applying Various Methods of Calculation in Determining the Blood-Absorbed Dose for Patients with Differentiated Thyroid Carcinoma
  • Influential Factors in the Preparation of 68Ga-DOTATATE
Show more Radiopharmacy & Adjunctive Medications

Similar Articles

  • Assessment of Residual [99mTc]Tc-Tetrofosmin Activity in Routine Nuclear Medicine Practice at Hospital Kuala Lumpur
  • The Impact of COVID-19 on First-Year Undergraduate Nuclear Medicine Students’ Practical Skills Training
  • Computer-Based Quality Assurance Program for Dose Calibrators
  • Quality Control in the Radiopharmacy
  • Adsorption of 99mTc-Radiopharmaceuticals onto Injection Vials and Syringes
See more

Keywords

  • quality assurance
  • 99mTc
  • radiopharmaceuticals
  • radiopharmacy
SNMMI

© 2025 SNMMI

Powered by HighWire
Alerts for this Article
Sign In to Email Alerts with your Email Address
Email this Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Validation of an Ergonomic Method of Withdrawing 99mTc-Radiopharmaceuticals
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Validation of an Ergonomic Method of Withdrawing 99mTc-Radiopharmaceuticals
Sandy Blondeel-Gomes, Solène Marie, Sabrina Loyeau, Julien Fouque, François Lokiec, Olivier Madar
Journal of Nuclear Medicine Technology Mar 2018, 46 (1) 49-52; DOI: 10.2967/jnmt.117.199133

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.